Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Share-based Compensation (2020 - 2025)

Gain Therapeutics has reported Share-based Compensation over the past 6 years, most recently at $401667.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $401667.0 for Q4 2025, up 11.78% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 24.56% YoY), and the annual figure for FY2025 was $1.8 million, down 24.56%.
  • Share-based Compensation for Q4 2025 was $401667.0 at Gain Therapeutics, down from $460005.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for GANX hit a ceiling of $1.5 million in Q2 2024 and a floor of -$22296.0 in Q4 2021.
  • Median Share-based Compensation over the past 5 years was $380498.0 (2024), compared with a mean of $475579.4.
  • Peak annual rise in Share-based Compensation hit 5852.18% in 2021, while the deepest fall reached 128.8% in 2021.
  • Gain Therapeutics' Share-based Compensation stood at -$22296.0 in 2021, then skyrocketed by 2605.79% to $558692.0 in 2022, then fell by 0.65% to $555059.0 in 2023, then tumbled by 35.26% to $359329.0 in 2024, then grew by 11.78% to $401667.0 in 2025.
  • The last three reported values for Share-based Compensation were $401667.0 (Q4 2025), $460005.0 (Q3 2025), and $522019.0 (Q2 2025) per Business Quant data.